Alimentiv and PhaseV to use machine learning for GI-focused drug trials
Alimentiv and artificial intelligence (AI) firm PhaseV have teamed up to take on challenging gastrointestinal disease clinical trials.
The partnership – financial terms of which were not disclosed – will use machine learning to optimize the design and execution of GI clinical trials, including those testing therapies for inflammatory bowel disease and celiac disease.
CEO Pierre Gaudreault said, “By combining our GI expertise with PhaseV’s advanced machine learning capabilities for trial simulation, design, and execution, we intend to significantly improve clinical study efficiency and outcomes.
“This will accelerate success for our sponsors and help address the growing burden of GI diseases more effectively,” he added.
Designing trials for candidate GI treatments is notoriously difficult. The high degree of heterogeneity seen in such diseases, combined with the placebo response rates with which they are associated, hinder protocol development.
As a result, most GI-focused clinical trials use adaptive designs, which allow sponsors to change studies that are in progress. Unfortunately, adaptive trials are more complex and costly to design and run.
To try and address this, PhaseV will use its technology to develop adaptive clinical trial protocols for Alimentiv’s customers.
PhaseV CEO Raviv Pryluk said, “GI clinical trials have historically been limited by challenges such as patient variability, complex disease mechanisms, and a lack of validated biomarkers. These challenges often complicate efficacy assessments of new treatments and lead to trial failure.
“Aligning our ML platform with Alimentiv’s GI trial leadership will help sponsors overcome these challenges, enabling more robust designs and execution that increase the likelihood of success,” he continued.
The partnership is similar to the accord PhaseV formed with UK-headquartered contract services firm Quanticate in April 2024.
Alimentiv has also established similar partnerships. In November 2023, for example, it teamed with AcelaBio and PharmaNest to use AI to improve trials focused on metabolic dysfunction-associated steatohepatitis (MASH).
DepositPhotos/Funtap